Go To Market Consulting Inc. And Debiopharm Group Collaborate To Identify Early Stage In-licensing Opportunities On The US West Coast
Go To Market focuses on developing B2B partnerships and end-customer relationships to create and grow leads and sales opportunities for companies in the biotechnology, pharmaceutical and device area. Go to Market has a combination of deep industry knowledge and international strategic, technical and commercial capabilities in life sciences. For more information on Go To Market Consulting Inc., please visit: http://www.go2mc.com
About Debiopharm Group™
Debiopharm Group™ (Debiopharm) is a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs. The group in-licenses, develops and/or co-develops promising biological and small molecule drug candidates having reached clinical development phases I, II or III, as well as earlier stage candidates. It develops its products for global registration and access to the largest number of patients worldwide. The products are out-licensed to pharmaceutical partners for sales and marketing. Debiopharm is also active in the field of companion diagnostics with a view to progressing in the area of personalized medicine. Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.
For more information about Debiopharm Group™, please visit: http://www.debiopharm.com.Debiopharm International SA Contact Beatrice Hirt Communication Coordinator firstname.lastname@example.org Tel.: +41(0)21-321-01-11 Additional Media Contacts In London Maitland Brian Hudspith email@example.com Tel: +44(0)20-7379-5151 In New York Russo Partners, LLC Martina Schwarzkopf, Ph.D. Account Executive firstname.lastname@example.org Tel: +1-212-845-4292 Go To Market Contact In San Francisco Maria Chiam Founder Maria.email@example.com Tel :+1-415-606-5839 SOURCE The Debiopharm Group
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts